Table 1.
Characteristics of the eligible studies.
| Study | Years | Design | N of Patients | Stage | Median Follow-Up | Median Age | N Stage (% of N+) | Median N of LNs Removed (Mean) | Reports | |
|---|---|---|---|---|---|---|---|---|---|---|
| T1-2/T3-4 | N0/N+ | compLND | incompLND | |||||||
| Kondo T et al. [24] | 2010 | Retro | 119 | 68/51 | 60.5 (mean) | 66.8 (mean) | 98/21 (17.6) | 9 (10.8) | 4 (4.4) | CSS |
| Fajkovic H et al. [22] | 2012 | Multicenter, retro | 817 | - | 33 (45.8, mean) | - | 595/222 (27.2) | 6 | 2 | PFS, CSS |
| Kobayashi K et al. [25] | 2015 | Retro | 54 | 10/45 | 33 | 69 | 14/40 (13.2) | 8.5 | 5 | OS |
| Chappidi MR et al. [10] | 2016 | Retro (SEER data) | 721 | 309/410 | 28 | - | 466/255 (31.2) | 5 | 1 | CSS, OS |
| Zareba P et al. [26] | 2017 | Retro | 2918 | 1433/1485 | 44 | 71 | 2151/767 (26.3) | Per 5 LNs | - | OS |
| Winer AG et al. [23] | 2017 | Retro | 442 | 303/139 | 42 | 70 | - | Per 5 LNs | - | PFS, CSS |
N = number; LN = lymph node; compLND = complete lymphadenectomy; incompLND = incomplete lymphadenectomy; Retro = retrospective; CSS = cancer specific survival; PFS = progression free survival; OS = overall survival.